comparemela.com

Latest Breaking News On - Pharma analyst - Page 3 : comparemela.com

GlobalData : Early diagnosis continues to pose challenges for Parkinson s disease-modifying therapies, says GlobalData -March 11, 2024 at 10:19 am EDT

11 Mar, 2024 Early diagnosis continues to pose challenges for Parkinson s disease-modifying therapies, says GlobalData Share .

Christie wongInternational conference on alzheimerPharma analystDrug database

Takeda oncology pipeline remains robust despite shift in focus from CAR-T to allogeneic cell therapies, says GlobalData

Takeda oncology pipeline remains robust despite shift in focus from CAR-T to allogeneic cell therapies, says GlobalData
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

Sasmitha sahuMemorial sloan kettering cancer centerGlobaldata pharma intelligence center drugsNoile immune biotechCrescendo biologicsPharma analyst

Takeda oncology pipeline remains robust despite shift in focus from CAR-T to allogeneic cell therapies, says GlobalData

Takeda oncology pipeline remains robust despite shift in focus from CAR-T to allogeneic cell therapies, says GlobalData

Sasmitha sahuMemorial sloan kettering cancer centerGlobaldata pharma intelligence center drugsNoile immune biotechCrescendo biologicsPharma analyst

Otsuka s new formulations to offset Abilify Maintena dual patent expiry impact, says GlobalData - Pharma News

Otsuka s new formulations to offset Abilify Maintena dual patent expiry impact, says GlobalData - Pharma News
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

Abilify asimtufiiEleni tokaliAbilify maintenaAbilify maintena aripiprazoleOtsuka pharmaceuticalDrugs databasePharma analyst

Otsuka s new formulations to offset Abilify Maintena dual patent expiry impact, says GlobalData

Otsuka Pharmaceutical is poised for a strategic transition as it approaches the loss of market exclusivity of Abilify Maintena (Aripiprazole) in Europe and the US in October 2024. This significant development signals a forthcoming shift in the drug’s sales trajectory, highlighting Otsuka’s readiness to embrace .

Abilify maintenaAbilify asimtufiiAbilify maintena aripiprazoleEleni tokaliOtsuka pharmaceuticalDrugs databasePharma analyst

vimarsana © 2020. All Rights Reserved.